+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

US Glioma - Market Insight, Epidemiology And Market Forecast - 2032

  • PDF Icon

    Report

  • 200 Pages
  • April 2023
  • Region: United States
  • DelveInsight
  • ID: 5780804
This Glioma Market - Market Insights, Epidemiology and Market Forecast- 2032 report delivers an in-depth understanding of the glioma, historical and forecasted epidemiology as well as the glioma market trends in the United States.

Glioma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted the US market size from 2019 to 2032. The report also covers current glioma treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
Study Period: 2019-2032

Glioma Disease Understanding and Treatment Algorithm

Glioma Overview

Glioma is the most common form of central nervous system (CNS) neoplasm originating from glial cells. They are very diffusely infiltrative tumors that affect the surrounding brain tissue. Three common types of gliomas are classified based on phenotypic cell characteristics: Astrocytomas, ependymomas, and oligodendrogliomas. Gliomas are caused by the accumulation of genetic mutations in glial stem or progenitor cells, leading to their uncontrolled growth. Gliomas are further classified into Grade I-IV. Among these Grades I-IV, glioblastoma (GBM Grade IV) is the most malignant type, while pilocytic astrocytomas (Grade I) are the least malignant brain tumors. IDH1 and IDH2 are the most commonly mutated genes in low-grade glioma, with mutations estimated to occur in > 70% of cases.

Glioma Diagnosis

The diagnosis of glioma includes neurological exams (this exam tests vision, hearing, speech, strength, sensation, balance, coordination, reflexes and the ability to think and remember), angiograms, magnetic resonance imaging (MRI) and computerized tomography (CT), surgical biopsy and others.

Glioma Treatment

Therapeutic management depends on the type of glioma, its size and location, and the specific characteristics of the patient. Especially in patients where the tumor cannot be entirely removed because it invades the brain in crucial areas or is not accessible, chemotherapy and radiation therapy will follow surgery. The standard treatment regimen includes surgery, chemotherapy, and radiation. Chemotherapy includes carmustine (BCNU), lomustine (CCNU), or gleostine (generic), Gliadel wafer (biodegradable discs infused with BCNU), temozolomide (TEMODAR) cisplatin, carboplatin, etoposide and irinotecan. They may be given as a single agent or in combination i.e. PCV (procarbazine, CCNU, and vincristine), carboplatin/ etoposide. The drugs most commonly used to treat brain tumors are temozolomide (TEMODAR) and bevacizumab (AVASTIN). In addition to chemotherapy, medication prescribed to individuals with gliomas includes anti-epileptic medication, anti-coagulation medication, and corticosteroids, to alleviate neurological symptoms caused by fluid accumulation around the tumor

Glioma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Glioma, Grade-specific Cases of Glioma, Age-specific Cases of Glioma, and Type-specific Cases of Glioma in the US market covering the United States from 2019 to 2032.

Key Findings

This section provides glimpse of the glioma epidemiology in the US

Country Wise- Glioma Epidemiology

  • The epidemiology segment also provides the glioma epidemiology data and findings across the United States
  • The Total Incident Cases of Glioma in the United States comprised of more than 19,000 cases in 2022 and are projected to increase during the forecast period
  • In the United States, of all the grades, Grade IV accounted for the highest number of incident cases followed by Grade II glioma, while Grade I had the least number of cases.
  • In the United States, among all the age groups, 60-74 years accounted for the highest number of glioma cases, in 2022, followed by the age-group 45-59 years
  • In 2022, among all the types, glioblastoma contributed to the highest number of glioma cases, followed by diffuse astrocytoma and anaplastic astrocytoma in the United States.

Glioma Drug Chapters

Drug chapter segment of the glioma report encloses the detailed analysis of glioma marketed drugs and emerging (Phase-III and Phase II and Phase I/II) pipeline drugs. It also helps to understand the glioma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

AVASTIN: Genentech

AVASTIN (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. In December 2017, the US FDA granted full approval of bevacizumab (AVASTIN) for the treatment of adults with recurrent GBM that has progressed following prior therapy.

TEMODAR/TEMODAL: Merck

The active pharmaceutical ingredient in TEMODAR/TEMODAL, is an imidazotetrazine derivative of the alkylating agent dacarbazine. Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for GBM. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. In July 2006, the Japan Ministry of Health, Labor and Welfare (MHLW) approved TEMODAL (R) (temozolomide) Capsules for the treatment of malignant glioma.

Note: Detailed Current therapies assessment will be provided in the full report of glioma

Emerging Drugs

Ofranergene obadenovec (VB-111): VBL Therapeutics

Ofranergene obadenovec (VB-111) is a first-in-class, targeted anticancer gene-therapy agent that is being developed by VBL Therapeutics to treat a wide range of solid tumors such as GBM. It is a non-replicating adenovirus 5 (Ad-5, El-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels and leads to vascular disruption. The drug has been rewarded Orphan Drug Designation from both US FDA and EMA for the treatment of patients with GBM. In addition, it has also been granted Fast Track Designation by the US FDA for prolongation of survival in patients with rGBM. Currently, the drug has completed phase III stage of clinical development for the patients with rGBM. In November 2017, VBL Therapeutics signed an exclusive license agreement with NanoCarrier for the development, commercialization, and supply of ofranergene obadenovec (VB-111) in Japan.

Trans Sodium Crocetinate: Diffusion Pharmaceuticals

Trans Sodium Crocetinate (TSC), being investigated by Diffusion Pharmaceuticals, is a first-in-class small molecule that, by its novel proprietary mechanism, safely reoxygenates oxygen-deprived tissue. It can act alone or with other treatments and presents opportunities in unmet medical needs across several markets. It can be used to enhance the cancer-killing power of radiation and chemotherapy for treating patients with GBM.

Selinexor (KPT-330): Karyopharm Therapeutics

Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export/SINE compound in development by Karyopharm Therapeutics. It functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function; this is supposed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. The drug has been approved with a brand name XPOVIO for patients in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. The phase II (KING) study was terminated due to sponsor decision.

Vorasidenib (AG-881): Servier

Vorasidenib (AG-881), a first-in-class, dual inhibitor of mIDH1/2, was specifically developed for improved penetration across the blood-brain barrier and showed brain penetrance and reduced tumor growth in an orthotopic model of mIDH glioma. Phase I interim data suggested that both tumor-intrinsic and -extrinsic mechanisms underlie 2-HG suppression by vorasidenib and ivosidenib. Vorasidenib demonstrated a favorable safety profile and is currently being evaluated in the registration-enabling Phase III INDIGO study as a potential treatment for patients with residual or recurrent Grade II low-grade glioma.

Tovorafenib (DAY101): Day One Biopharmaceuticals

Tovorafenib (DAY101) is an investigational, oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which may offer an important alternative for people with primary brain tumors or brain metastases of solid tumors. Currently, DAY101 is under evaluation in a pivotal Phase II clinical trial (FIREFLY-1) evaluating its safety and efficacy in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma (pLGG) harboring a known BRAF alteration. Based on the initial FIREFLY-1 data, the company plans to expand the development of tovorafenib as a front-line therapy for patients newly diagnosed with pLGG and anticipates reporting topline data from this trial in the first quarter of 2023, and if the data are supportive, the company expects to file an NDA to FDA, in first of half 2023.

Note: Detailed emerging therapies assessment will be provided in the final report.

Glioma Market Outlook

Glioma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.

The first step in treating glioma is a surgical procedure to make a diagnosis, to relieve pressure on the brain, and to remove as much tumor as possible safely. Glioma surgery is performed to achieve a “maximum safe resection,” or removing as much of the tumor as possible without causing lasting neurological damage.

It is interesting to note that the emerging market of glioma includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.

The glioma pipeline possessed multiple potential drugs in late- and mid-stage developments to be launched shortly. Key players involved in robust research and development include Paxalisib (GDC-0084): Kazia Therapeutics, LAM561: Laminar Pharmaceuticals, Tasa-denoturev (DNX-2401): DNAtrix and, others are some of the major players that are going to alter the market dynamics in the coming years.

Key Findings

This section includes a glimpse of the glioma the United States market.
  • The total market size of glioma in the United States is more than USD 600 million in 2022 and is projected to grow during the forecast period (2022-2032).
  • According to the estimates, the highest market size of glioma is from the United States, in 2022.
  • In the United States, among the current therapies for glioma Optune ± TMZ captured the highest revenue in 2022.

The United States Market Outlook

The total market size of glioma in the United States is expected to increase during the study period (2019-2032).

Analyst Commentary

  • The market of glioma is currently using Temozolomide (TEMODAR) and Bevacizumab (AVASTIN) as approved therapies, but the market lacks an effective strategy to cure glioma, which provides a lucrative opportunity to develop more treatment options.
  • Advancement in the understanding of molecular mechanisms and gene mutations are leading to more promising and tailored therapeutic approaches for glioma patients
  • Owing to the launch of Bevacizumab biosimilars, a reduction in cost burden can be witnessed
  • Despite a strong pipeline, most of the emerging therapies tend to fail in the high phase trials
  • There is a substantial market opportunity for vaccines and oncolytic virus therapies in glioma

Glioma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs expected to get launched in the market during the study period 2019-2032. The analysis covers glioma market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- Kintara Therapeutics ‘VAL-083' is a DNA-targeting agent, in three distinct biomarker-driven glioma patient populations. VAL-083 can cross the blood-brain barrier (BBB), has biological and tumor affecting activity against a range of cancers, including glioma and ovarian cancer. As per our analysis VAL-083, drug uptake in the US is expected to be medium-fast with peak share of 12%, years to peak would be 7 years in first line, whereas in second-line peak share is estimated to 5.5%.

Glioma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II and Phase I/II stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for glioma emerging therapies.

KOL-Views

To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like Chief Executive Officer, VBL Therapeutics, Chief executive officer, DNAtrix, Chief Medical Officer, VBI Vaccines, Chief Medical Officer, Kazia Therapeutics and others. Their opinion helps to understand and validate current and emerging therapies treatment patterns or glioma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs competitive and market Intelligence analysis of the glioma market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of glioma, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the glioma epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for glioma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of glioma market; historical and forecasted is included in the report, covering the US drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the US glioma market.

Report Highlights

  • In the coming years, glioma market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence glioma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • As per the analysis, the type- specific cases of glioma include incident cases of diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytic tumors, pilocytic astrocytoma, and others
  • Expected Launch of potential therapies, Paxalisib (GDC-0084): Kazia Therapeutics, LAM561: Laminar Pharmaceuticals, Tasa-denoturev (DNX-2401): DNAtrix and others might change the landscape in treatment of glioma.

Glioma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Glioma Pipeline Analysis
  • Glioma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Glioma Report Key Strengths

  • Ten Years Forecast
  • The US Coverage
  • Glioma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Glioma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • SWOT
  • Attribute Analysis

Key Questions Answered

Market Insights:

  • What was the glioma market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the glioma total market size as well as market size by therapies across the US during the study period (2019-2032)?
  • What are the key findings pertaining to the market across the US and which country will have the largest glioma market size during the study period (2019-2032)?
  • At what CAGR, the glioma market is expected to grow at the US level during the study period (2019-2032)?
  • What would be the glioma market outlook across the US during the study period (2019-2032)?
  • What would be the glioma market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of glioma?
  • What is the historical glioma patient pool in the United States?
  • What would be the forecasted patient pool of glioma at the US level?
  • What will be the growth opportunities across the US with respect to the patient population pertaining to glioma?
  • At what CAGR the population is expected to grow across the US during the study period (2019-2032)?

Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of glioma? What are the current treatment guidelines for the treatment of glioma in the US?
  • How many companies are developing therapies for the treatment of glioma?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of glioma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the glioma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for glioma and their status?
  • What are the key designations that have been granted for the emerging therapies for glioma?
  • What are the US historical and forecasted market of glioma?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the glioma.
  • To understand the future market competition in the glioma market and Insightful review of the SWOT analysis of glioma.
  • Organize sales and marketing efforts by identifying the best opportunities for glioma in the US.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for glioma market.
  • To understand the future market competition in the glioma market.

Table of Contents

1. Key Insights2. Report Introduction3. Executive Summary of Glioma4. Key Events5. Epidemiology and Market Forecast Methodology
6. Glioma Market Overview at a Glance
6.1. Market Share (%) Distribution of Glioma by Therapies in 2022
6.2. Market Share (%) Distribution of Glioma by Therapies in 2032
7. Disease Background and Overview: Gliomas
7.1. Introduction
7.2. Classification of gliomas
7.2.1. Low-grade Gliomas
7.2.2. High-grade Gliomas
7.3. Signs and symptoms
7.4. Causes
7.5. Diagnosis
7.5.1. Neurological exams
7.5.2. Angiograms
7.5.3. Computerized tomography (CT)
7.5.4. Magnetic resonance imaging (MRI)
7.5.5. Perfusion MRI
7.5.6. MR spectroscopy
7.5.7. Histological diagnosis
7.5.8. Surgical biopsy
8. Treatment and management
8.1. Treatment of LGGs
8.2. Treatment of HGGs
8.3. Symptom management
8.4. Treatment guidelines and recommendations
8.4.1. American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma (2017)
8.4.2. American Society of Therapeutic Radiology and Oncology (ASTRO) Clinical Practice Guideline for LGGs (2021)
8.4.3. National Comprehensive Cancer Network [NCCN] Guidelines for the Management of Gliomas (2022)
8.4.4. National Institute for Health and Care Excellence Guidelines for the Management of Newly Diagnosed Glioblastoma (2021)
9. Epidemiology and Patient Population of Glioma in the United States
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. The United States
9.3.1. Total Incident Cases of Glioma in the United States
9.3.2. Grade-specific Cases of Glioma in the United States
9.3.3. Age-specific Cases of Glioma in the United States
9.3.4. Type-specific Cases of Glioma in the United States
10. Patient Journey11. Key Endpoints in Glioma
12. Marketed Products
12.1. Key Competitors
12.2. OPTUNE: Novocure Limited
12.2.1. Product description
12.2.2. Regulatory milestones
12.2.3. Other developmental activities
12.2.4. Current pipeline activity
12.2.5. Safety and efficacy
12.2.6. Product profile
12.3. AVASTIN (bevacizumab): Genentech
12.3.1. Product description
12.3.2. Regulatory milestones
12.3.3. Other developmental activities
12.3.4. Safety and efficacy
12.3.5. Product profile
12.4. TEMODAR (temozolomide): Merck
12.4.1. Product description
12.4.2. Regulatory milestones
12.4.3. Other development activities
12.4.4. Current pipeline activity
12.4.5. Safety and efficacy
12.4.6. Product profile
12.5. DELYTACT: Daiichi Sankyo
12.5.1. Product description
12.5.2. Regulatory milestones
12.5.3. Other developmental activities
12.5.4. Safety and efficacy
12.5.5. Product profile
12.6. TAFINLAR (dabrafenib) + MEKINIST (trametinib): Novartis
12.6.1 .Product description
12.6.2 .Regulatory milestones
12.6.3 .Other Developmental Activities
12.6.4 .Clinical development
12.6.5 .Safety and efficacy
12.6.6 .Product profile
13. Emerging Drugs
13.1. Key Competitors
13.2. Regorafenib: Bayer
13.2.1. Product description
13.2.2. Other developmental activities
13.2.3. Clinical development
13.2.4. Safety and efficacy
13.3. ONC201: Chimerix
13.3.1. Product description
13.3.2. Other developmental activities
13.3.3. Clinical development
13.3.4. Safety and efficacy
13.4. AV-GBM-1: Aivita Biomedical
13.4.1. Product description
13.4.2. Clinical development
13.4.3. Safety and efficacy
13.5. Enzastaurin (DB-102): Denovo Biopharma
13.5.1. Product description
13.5.2. Other developmental activities
13.5.3. Clinical development
13.5.4. Safety and efficacy
13.6. DCVax-L: Northwest Therapeutics
13.6.1. Product description
13.6.2. Other developmental activity
13.6.3. Clinical development
13.6.4. Safety and efficacy
13.7. Ofranergene Obadenovec (VB-111): VBL Therapeutics
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical development
13.7.4. Safety and efficacy
13.8. LAM561 (2-OHOA): Laminar Pharmaceuticals
13.8.1. Product description
13.8.2. Other developmental activities
13.8.3. Clinical development
13.8.4. Safety and efficacy
13.9. MEDI4736 (durvalumab): MedImmune
13.9.1. Product description
13.9.2. Clinical Development
13.9.3. Safety and efficacy
13.10. Tasadenoturev (DNX-2401): DNAtrix
13.10.1. Product description
13.10.2. Other developmental activities
13.10.3. Clinical development
13.10.4. Safety and efficacy
13.11. ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
13.11.1. Product description
13.11.2. Other developmental activities
13.11.3. Clinical development
13.11.4. Safety and efficacy
13.12. IGV-001: Imvax
13.12.1. Product description
13.12.2. Other developmental activities
13.12.3. Clinical development
13.12.4. Safety and efficacy
13.13. SurVaxM: MimiVax
13.13.1. Product description
13.13.2. Other developmental activities
13.13.3. Clinical development
13.13.4. Safety and efficacy
13.14. Berubicin: CNS Pharmaceuticals
13.14.1. Product description
13.14.2. Other developmental activities
13.14.3. Clinical development
13.14.4. Safety and efficacy
13.15. GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)
13.15.1. Product description
13.15.2. Other developmental activities
13.15.3. Clinical development
13.15.4. Safety and efficacy
13.16. Lerapolturev + Pembrolizumab: Istari Oncology
13.16.1. Product description
13.16.2. Other developmental activities
13.16.3. Clinical development
13.16.4. Safety and efficacy
13.17. SONALA-001 + Exablate 2.0 Device: SonALAsense
13.17.1. Product description
13.17.2. Clinical development
13.17.3. Safety and efficacy
13.18. VAL-083 (dianhydrogalactitol): Kintara Therapeutics
13.18.1. Product description
13.18.2. Other developmental activities
13.18.3. Clinical development
13.18.4. Safety and efficacy
13.19. Pomalidomide: Bristol Myers Squibb
13.19.1. Product description
13.19.2. Other developmental activities
13.19.3. Clinical development
13.19.4. Safety and efficacy
13.20. MDNA55: Medicenna Therapeutics
13.20.1. Product description
13.20.2. Other developmental activities
13.20.3. Clinical development
13.20.4. Safety and efficacy
13.21. BMX-001: BioMimetix
13.21.1. Product description
13.21.2. Other developmental activity
13.21.3. Clinical development
13.21.4. Safety and efficacy
13.22. Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme
13.22.1. Product description
13.22.2. Clinical development
13.22.3. Safety and efficacy
13.23. Paxalisib (GDC-0084): Kazia Therapeutics
13.23.1. Product description
13.23.2. Other developmental activities
13.23.3. Clinical development
13.23.4. Safety and efficacy
13.24. OKN-007: Oblato
13.24.1. Product description
13.24.2. Other developmental Activity
13.24.3. Clinical development
13.24.4. Safety and efficacy
13.25. Temferon: Genenta Science
13.25.1. Product description
13.25.2. Clinical development
13.25.3. Safety and efficacy
13.26. EO2401: Enterome
13.26.1. Product description
13.26.2. Clinical development
13.26.3. Safety and efficacy
13.27. INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals
13.27.1. Product description
13.27.2. Clinical development
13.27.3. Safety and efficacy
13.28. Selinexor (KPT-330): Karyopharm Therapeutics
13.28.1. Product description
13.28.2. Clinical development
13.28.3. Safety and efficacy
13.29. Olutasidenib (FT-2102): Forma Therapeutics
13.29.1. Product description
13.29.2. Other developmental activities
13.29.3. Clinical development
13.29.4. Safety and efficacy
13.30. VBI-1901: VBI Vaccines
13.30.1. Product description
13.30.2. Other developmental activities
13.30.3. Clinical development
13.30.4. Safety and efficacy
13.31. NOX-A12 (Olaptesed Pegol): TME Pharma
13.31.1. Product description
13.31.2. Other developmental activities
13.31.3. Clinical development
13.31.4. Safety and efficacy
13.32. Tovorafenib (DAY101): Day One Biopharmaceuticals
13.32.1. Product description
13.32.2. Other developmental activities
13.32.3. Clinical development
13.32.4. Safety and efficacy
13.33. Vorasidenib (AG-881): Servier
13.33.1. Product description
13.33.2. Other developmental activities
13.33.3. Clinical development
13.33.4. Safety and efficacy
13.34. Eflornithine: Orbus Therapeutics
13.34.1. Product description
13.34.2. Other developmental activities
13.34.3. Clinical development
13.34.4. Safety and efficacy
13.35. TVI-Brain-1: TVAX Biomedical
13.35.1. Product description
13.35.2. Other developmental activities
13.35.3. Clinical development
13.36. AB-218: AnHeart Therapeutics
13.36.1. Product description
13.36.2. Other developmental activities
13.36.3. Clinical development
13.36.4. Safety and efficacy
13.37. BGB-290: Beigene
13.37.1. Product description
13.37.2. Clinical development
13.37.3. Safety and efficacy
13.38. Mirdametinib: SpringWorks Therapeutics
13.38.1. Product description
13.38.2. Other developmental activities
13.38.3. Clinical development
13.38.4. Safety and efficacy
13.39. FT-2102 (Olutasidenib): Forma Therapeutics
13.39.1. Product description
13.39.2. Other developmental activities
13.39.3. Clinical development
13.39.4. Safety and efficacy
13.40. Vinblastine + Bevacizumab: Hoffmann-La Roche
13.40.1. Product description
13.40.2. Clinical development
13.40.3. Safety and efficacy
13.41. Cobimetinib: Hoffmann-La Roche
13.41.1. Product description
13.41.2. Clinical development
13.41.3. Safety and efficacy
13.42. PEMAZYRE (Pemigatinib): Incyte Corporation
13.42.1. Product description
13.42.2. Clinical development
13.43. VERZENIO (abemaciclib): Eli Lilly
13.43.1. Product description
13.43.2. Clinical development
13.43.3. Safety and efficacy
14. Glioma: United States Major Market Analysis
14.1. Market Outlook
14.2. Conjoint Analysis
14.3. United States Market Size
14.3.1. Total Market Size of Glioma in the United States
14.3.2. Market Size of Glioma by Current and Emerging Therapies in the United States
15. Unmet Needs16. SWOT Analysis17. KOL Views
18. Market Access and Reimbursement for Glioma
18.1. United States
19. Appendix
19.1. Bibliography
19.2. Report Methodology
20. Publisher Capabilities21. Disclaimer22. About the Publisher
List of Tables
Table 1: Key Events
Table 2: Grading Within Types
Table 3: Glioma Grading Scale
Table 4: Indication and Timing for RT
Table 5: Optimal Dose of RT and Target Volume Based on Risk Stratification
Table 6: Adult Glioma: WHO Grade 1
Table 7: Adult Glioma: Oligodendroglioma (IDH-mutant, 1p19q Codeleted)
Table 8: Adult Glioma: IDH-Mutant Astrocytoma
Table 9: Adjuvant Treatment of GBM Based on age and Karnofsky Performance Status
Table 10: Summary of Recommendations
Table 11: Key Treatment Recommendations for Adult Patients with Common Diffuse Gliomas
Table 12: Total Incident Cases of Glioma in the US (2019-2032)
Table 13: Grade-specific Cases of Glioma in the US (2019-2032)
Table 14: Age-specific Cases of Glioma in the US (2019-2032)
Table 15: Type-specific Cases of Glioma in the US (2019-2032)
Table 16: Comparison of Marketed Products
Table 17: OPTUNE, Clinical Trial Description, 2022
Table 18: TEMODAR, Clinical Trial Description, 2022
Table 19: Recommended Weight-based Dosing for TAFINLAR and MEKINIST for Liquid Formulations
Table 20: Trametinib + Dabrafenib ,Clinical Trial Description, 2022
Table 21: Comparison of Emerging Drugs
Table 22: Regorafenib, Clinical Trial Description, 2022
Table 23: ONC201, Clinical Trial Description, 2022
Table 24: AV-GBM-1, Clinical Trial Description, 2022
Table 25: Enzastaurin Hydrochloride, Clinical Trial Description, 2022
Table 26: DCVAX-L, Clinical Trial Description, 2022
Table 27: VB-111, Clinical Trial Description, 2022
Table 28: 2-OHOA, Clinical Trial Description, 2022
Table 29: MEDI4736, Clinical Trial Description, 2022
Table 30: Tasadenoturev (DNX-2401), Clinical Trial Description, 2022
Table 31: ITI-1000, Clinical Trial Description, 2022
Table 32: IGV-001, Clinical Trial Description, 2022
Table 33: SurVaxM, Clinical Trial Description, 2022
Table 34: Berubicin, Clinical Trial Description, 2022
Table 35: Sitoiganap, Clinical Trial Description, 2022
Table 36: Lerapolturev, Clinical Trial Description, 2022
Table 37: SONALA-001 + Exablate 2.0 Device, Clinical Trial Description, 2022
Table 38: VAL-083 (dianhydrogalactitol), Clinical Trial Description, 2022
Table 39: Pomalidomide (CC-4047), Clinical Trial Description, 2022
Table 40: MDNA55, Clinical Trial Description, 2022
Table 41: BMX-001, Clinical Trial Description, 2022
Table 42: Pembrolizumab ± Lenvatinib, Clinical Trial Description, 2022
Table 43: Paxalisib (GDC-0084), Clinical Trial Description, 2022
Table 44: OKN-007, Clinical Trial Description, 2022
Table 45: Temferon, Clinical Trial Description, 2022
Table 46: EO2401, Clinical Trial Description, 2022
Table 47: INO-5401+ INO-9012+ LIBTAYO, Clinical Trial Description, 2022
Table 48: Selinexor (KPT-330), Clinical Trial Description, 2022
Table 49: Olutasidenib, Clinical Trial Description, 2022
Table 50: VBI-1901, Clinical Trial Description, 2022
Table 51: NOX-A12 (Olaptesed Pegol), Clinical Trial Description, 2022
Table 52: DAY101, Clinical Trial Description, 2022
Table 53: Vorasidenib, Clinical Trial Description, 2022
Table 54: Eflornithine, Clinical Trial Description, 2022
Table 55: TVI-Brain-1, Clinical Trial Description, 2022
Table 56: AB-218, Clinical Trial Description, 2022
Table 57: BGB-290, Clinical Trial Description, 2022
Table 58: Mirdametinib, Clinical Trial Description, 2022
Table 59: Olutasidenib, Clinical Trial Description, 2022
Table 60: Vinblastine + Bevacizumab, Clinical Trial Description, 2022
Table 61: Cobimetinib, Clinical Trial Description, 2022
Table 62: Pemigatinib, Clinical Trial Description, 2022
Table 63: Verzenio, Clinical Trial Description, 2022
Table 64: Limitations of Current Treatments in Glioblastoma
Table 65: Key Market Forecast Assumptions for ITI-1000
Table 66: Key Market Forecast Assumptions for SurVaxM
Table 67: Key Market Forecast Assumptions for AV-GBM-1
Table 68: Key Market Forecast Assumptions for Tasadenoturev (DNX-2401)
Table 69: Key Market Forecast Assumptions for EO2401
Table 70: Key Market Forecast Assumptions for berubicin
Table 71: Key Market Forecast Assumptions for sitoiganap
Table 72: Key Market Forecast Assumptions for lerapolturev + pembrolizumab
Table 73: Key Market Forecast Assumptions for INO-5401+ INO-9012+ LIBTAYO (cemiplimab)
Table 74: Key Market Forecast Assumptions for Temferon
Table 75: Key Market Forecast Assumptions for VAL-083
Table 76: Key Market Forecast Assumptions for VBI-1901
Table 77: Key Market Forecast Assumptions for MDNA55
Table 78: Key Market Forecast Assumptions for DCVax
Table 79: Key Market Forecast Assumptions for Regorafenib
Table 80: Key Market Forecast Assumptions for LAM561 (2-OHOA)
Table 81: Key Market Forecast Assumptions for ONC201
Table 82: Key Market Forecast Assumptions for Paxalisib
Table 83: Key Market Forecast Assumptions for Enzastaurin
Table 84: Total Market Size of Glioma in the United States
Table 85: Market Size of Glioma by Current and Emerging Therapies in the United States
List of Figures
Figure 1: Changes From WHO 2016 to 2021 Classification
Figure 2: Types of Gliomas
Figure 3: Generalized Transcription Pathways Related to Glioblastoma Disease
Figure 4: NCCN Guidelines for Treatment of GBM (age =70)
Figure 5: NCCN Guidelines for Treatment of GBM (age >70)
Figure 6: Management Options for People with Newly Diagnosed Grade IV Glioma (GBM)
Figure 7: Global Heat Map of Brain and CNS Tumor
Figure 8: Total Incident Cases of Glioma in the US (2019-2032)
Figure 9: Grade-specific Cases of Glioma in the US (2019-2032)
Figure 10: Age-specific Cases of Glioma in the US (2019-2032)
Figure 11: Type-specific Cases of Glioma in the US (2019-2032)
Figure 12: Novocure's second-generation OPTUNE System
Figure 13: GBM AGILE two-stage study design
Figure 14: Total Market Size of Glioma in the United States
Figure 15: Market Size of Glioma by Current and Emerging Therapies in the United States

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bayer
  • Chimerix
  • Aivita Biomedical
  • Denovo Biopharma
  • Northwest Therapeutics
  • VBL Therapeutics
  • Laminar Pharmaceuticals
  • MedImmune
  • DNAtrix
  • Immunomic Therapeutics
  • Imvax
  • MimiVax
  • CNS Pharmaceuticals
  • Epitopoietic Research Corporation (ERC)
  • Istari Oncology
  • SonALAsense
  • Kintara Therapeutics
  • Bristol Myers Squibb
  • Medicenna Therapeutics
  • BioMimetix
  • Eisai and Merck Sharp & Dohme
  • Kazia Therapeutics
  • Oblato
  • Genenta Science
  • Enterome
  • Inovio Pharmaceuticals
  • Karyopharm Therapeutics
  • Forma Therapeutics
  • VBI Vaccines
  • TME Pharma
  • Day One Biopharmaceuticals
  • Servier
  • Orbus Therapeutics
  • TVAX Biomedical
  • AnHeart Therapeutics
  • Beigene
  • SpringWorks Therapeutics
  • Forma Therapeutics
  • Hoffmann-La Roche
  • Incyte Corporation
  • Eli Lilly